Quale sarebbe il prezzo per Psyence Biomedical Ltd. (PBM)

Il prezzo per Psyence Biomedical Ltd. (PBM) è $3.20

Qual è la capitalizzazione di mercato per Psyence Biomedical Ltd. (PBM)

La capitalizzazione di mercato per Psyence Biomedical Ltd. (PBM) è $60.86K

Psyence Biomedical Ltd. (PBM) Prezzo e Capitalizzazione di Mercato

Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.

Il prezzo per PBM	Attivo B	Capitalizzazione del mercato a B	Risultati
$286,436,535 $60.86K	NVDA	$5.448T	+8,951,141,613.39%
$234,322,753 $60.86K	AAPL	$4.457T	+7,322,585,917.73%
$220,135,916 $60.86K	GOOG	$4.187T	+6,879,247,275.84%
$194,358,958 $60.86K	MSFT	$3.697T	+6,073,717,345.99%
$151,789,417 $60.86K	AMZN	$2.887T	+4,743,419,189.59%

Il prezzo per PBM

Attivo B

Capitalizzazione del mercato a B

Risultati

$286,436,535 $60.86K